GMABGenmabRunning, no new patients
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 264 (final count)
- Started
- Jun 14, 2022
- Main results expected
- Nov 2032
- Fully finished
- Nov 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Dose-Limiting Toxicities (DLT)
Measured over: Up to Approximately 5 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05283720 · record last updated 2026-07-07 · checked 2026-11-09 15:47 UTC